...
首页> 外文期刊>BMC Complementary and Alternative Medicine >Efficacy and safety of electroacupuncture in acute decompensated heart failure: a study protocol for a randomized, patient- and assessor-blinded, sham controlled trial
【24h】

Efficacy and safety of electroacupuncture in acute decompensated heart failure: a study protocol for a randomized, patient- and assessor-blinded, sham controlled trial

机译:电针治疗急性失代偿性心力衰竭的疗效和安全性:一项针对患者,评估者和盲人的随机对照试验的研究方案

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background The purpose of this trial is to evaluate the effectiveness and safety of electroacupuncture in the treatment of acute decompensated heart failure compared with sham electroacupuncture. Methods This protocol is for a randomized, sham controlled, patient- and assessor-blinded, parallel group, single center clinical trial that can overcome the limitations of previous trials examining acupuncture and heart failure. Forty-four acute decompensated heart failure patients admitted to the cardiology ward will be randomly assigned into the electroacupuncture treatment group ( n =?22) or the sham electroacupuncture control group ( n =?22). Participants will receive electroacupuncture treatment for 5?days of their hospital stay. The primary outcome of this study is the difference in total diuretic dose between the two groups during hospitalization. On the day of discharge, follow-up heart rate variability, routine blood tests, cardiac biomarkers, high-sensitivity C-reactive protein (hs-CRP) level, and N-terminal pro b-type natriuretic peptide (NT-pro BNP) level will be assessed. Four weeks after discharge, hs-CRP, NT-pro BNP, heart failure symptoms, quality of life, and a pattern identification questionnaire will be used for follow-up analysis. Six months after discharge, major cardiac adverse events and cardiac function measured by echocardiography will be assessed. Adverse events will be recorded during every visit. Discussion The result of this clinical trial will offer evidence of the effectiveness and safety of electroacupuncture for acute decompensated heart failure. Trial registration Clinical Research Information Service: KCT0002249 .
机译:背景技术该试验的目的是评估电针与假电针治疗急性失代偿性心力衰竭的有效性和安全性。方法该方案适用于随机,假对照,患者和评估者盲目,平行组,单中心临床试验,该试验可以克服以前的针灸和心力衰竭试验的局限性。进入心脏病病房的44名急性失代偿性心力衰竭患者将被随机分为电针治疗组(n = 22)或假电针对照组(n = 22)。参与者将在住院期间的5天之内接受电针治疗。这项研究的主要结果是住院期间两组之间总利尿剂剂量的差异。出院当天,进行心率变异性检查,常规血液检查,心脏生物标志物,高敏C反应蛋白(hs-CRP)水平和N端前b型利尿钠肽(NT-pro BNP)水平将被评估。出院后四周,将使用hs-CRP,NT-pro BNP,心力衰竭症状,生活质量和模式识别问卷进行后续分析。出院后六个月,将评估通过超声心动图测量的主要心脏不良事件和心脏功能。每次访问期间都将记录不良事件。讨论该临床试验的结果将为电针治疗急性失代偿性心力衰竭的有效性和安全性提供证据。试用注册临床研究信息服务:KCT0002249。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号